Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05942001 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

StatusRecruiting
PhasePhase 1
Started2023-08-03
View on ClinicalTrials.gov ↗
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.

Amendment history 4 changes detected by DataLookout

2026-09-01
Trial arms changed: 1 → 4
2026-09-01
Primary completion pushed: 2025-08-31 → 2026-09
2026-09-01
Completion pushed: 2025-08-31 → 2026-09
2026-09-01
Interventions modified
Trial Details
NCT Number NCT05942001
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Prostate Cancer
Enrollment 100 participants
Start Date 2023-08-03
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-31